Tawanda Gumbo

11.5k total citations · 1 hit paper
197 papers, 7.6k citations indexed

About

Tawanda Gumbo is a scholar working on Infectious Diseases, Epidemiology and Pharmacology. According to data from OpenAlex, Tawanda Gumbo has authored 197 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 156 papers in Infectious Diseases, 130 papers in Epidemiology and 67 papers in Pharmacology. Recurrent topics in Tawanda Gumbo's work include Tuberculosis Research and Epidemiology (131 papers), Mycobacterium research and diagnosis (78 papers) and Antibiotics Pharmacokinetics and Efficacy (66 papers). Tawanda Gumbo is often cited by papers focused on Tuberculosis Research and Epidemiology (131 papers), Mycobacterium research and diagnosis (78 papers) and Antibiotics Pharmacokinetics and Efficacy (66 papers). Tawanda Gumbo collaborates with scholars based in United States, South Africa and Netherlands. Tawanda Gumbo's co-authors include Jotam G. Pasipanodya, Shashikant Srivastava, Arnold Louie, Devyani Deshpande, George L. Drusano, Richard D. Leff, Claudia Meek, Mark R. Deziel, Helen McIlleron and Paul G. Ambrose and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and SHILAP Revista de lepidopterología.

In The Last Decade

Tawanda Gumbo

190 papers receiving 7.4k citations

Hit Papers

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynami... 2006 2026 2012 2019 2006 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore
    2006 547 citations Arnold Louie, Tawanda Gumbo et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tawanda Gumbo United States 48 5.5k 4.1k 2.6k 1.1k 1.1k 197 7.6k
Charles A. Peloquin United States 57 7.8k 1.4× 5.9k 1.4× 3.2k 1.2× 1.0k 0.9× 1.7k 1.6× 317 11.7k
Eric L. Nuermberger United States 51 6.6k 1.2× 4.6k 1.1× 846 0.3× 878 0.8× 2.5k 2.4× 169 8.1k
William Hope United Kingdom 55 7.0k 1.3× 6.3k 1.5× 3.3k 1.3× 1.5k 1.4× 754 0.7× 240 11.2k
Stephen H. Gillespie United Kingdom 52 6.0k 1.1× 5.4k 1.3× 783 0.3× 1.1k 1.0× 1.7k 1.7× 263 10.2k
Rob E. Aarnoutse Netherlands 45 4.5k 0.8× 2.9k 0.7× 1.1k 0.4× 301 0.3× 730 0.7× 194 6.6k
J Grosset France 58 7.9k 1.4× 7.2k 1.8× 921 0.3× 1.1k 1.0× 2.3k 2.2× 258 10.5k
M. Hong Nguyen United States 49 7.2k 1.3× 5.6k 1.4× 999 0.4× 749 0.7× 699 0.7× 140 9.5k
Ethan Rubinstein Canada 45 2.4k 0.4× 2.4k 0.6× 1.8k 0.7× 1.8k 1.6× 1.0k 1.0× 140 6.8k
Véronique Dartois United States 56 6.6k 1.2× 4.7k 1.1× 659 0.2× 900 0.8× 3.8k 3.6× 202 10.2k
Martin J. Boeree Netherlands 51 5.4k 1.0× 4.9k 1.2× 529 0.2× 338 0.3× 910 0.9× 165 7.4k

Countries citing papers authored by Tawanda Gumbo

Since Specialization
Citations

This map shows the geographic impact of Tawanda Gumbo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tawanda Gumbo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tawanda Gumbo more than expected).

Fields of papers citing papers by Tawanda Gumbo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tawanda Gumbo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tawanda Gumbo. The network helps show where Tawanda Gumbo may publish in the future.

Co-authorship network of co-authors of Tawanda Gumbo

This figure shows the co-authorship network connecting the top 25 collaborators of Tawanda Gumbo. A scholar is included among the top collaborators of Tawanda Gumbo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tawanda Gumbo. Tawanda Gumbo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ferro, Beatriz E., Shashikant Srivastava, & Tawanda Gumbo. (2025). Ceftaroline pharmacokinetics/pharmacodynamics in the hollow-fibre model of Mycobacterium abscessus lung disease. PubMed. 2(9). 519–526.
2.
Singh, Sanjay, et al.. (2025). Comparative efficacy of tetracyclines against isolates of Mycobacterium avium complex. PubMed. 2(2). 113–115.
3.
Singh, Sanjay, David M. Engelthaler, Tania A. Thomas, et al.. (2025). Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis. Antimicrobial Agents and Chemotherapy. 69(2). e0108424–e0108424.
4.
Deshpande, Devyani, Shashikant Srivastava, & Tawanda Gumbo. (2024). Ertapenem's therapeutic potential for Mycobacterium avium lung disease in the hollow fibre model. International Journal of Antimicrobial Agents. 64(3). 107204–107204. 3 indexed citations
5.
Deshpande, Devyani, Gesham Magombedze, Shashikant Srivastava, & Tawanda Gumbo. (2024). Antibacterial action of penicillin against Mycobacterium avium complex. SHILAP Revista de lepidopterología. 1(8). 362–368. 1 indexed citations
6.
Singh, Sanjay, Tawanda Gumbo, Jann‐Yuan Wang, et al.. (2024). Imipenem Pharmacokinetics/Pharmacodynamics in Preclinical Hollow Fiber Model, Dose Finding in Virtual Patients, and Clinical Evidence of Efficacy for Mycobacterium abscessus Lung Disease. The Journal of Infectious Diseases. 231(6). 1521–1531. 3 indexed citations
7.
Singh, Sanjay, et al.. (2023). Sarecycline pharmacokinetics/pharmacodynamics in the hollow-fibre model of Mycobacterium avium complex: so near and yet so far. Journal of Antimicrobial Chemotherapy. 79(1). 96–99. 2 indexed citations
8.
Chirehwa, Maxwell, Richard Court, M De Kock, et al.. (2023). Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling. Antimicrobial Agents and Chemotherapy. 67(3). e0142622–e0142622. 5 indexed citations
9.
Singh, Sanjay, Jann‐Yuan Wang, Scott K. Heysell, et al.. (2023). Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus disease. International Journal of Antimicrobial Agents. 62(1). 106847–106847. 14 indexed citations
10.
Chirehwa, Maxwell, Elisa H. Ignatius, Richard Court, et al.. (2022). Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy. 77(9). 2489–2499. 7 indexed citations
11.
Srivastava, Shashikant, et al.. (2022). Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection. Antimicrobial Agents and Chemotherapy. 66(4). e0232021–e0232021. 3 indexed citations
12.
Court, Richard, Chad M. Centner, Maxwell Chirehwa, et al.. (2021). Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. International Journal of Infectious Diseases. 105. 688–694. 31 indexed citations
13.
Chirehwa, Maxwell, Richard Court, Lubbe Wiesner, et al.. (2021). Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients. Antimicrobial Agents and Chemotherapy. 65(10). e0027821–e0027821. 5 indexed citations
14.
Srivastava, Shashikant, Jann‐Yuan Wang, Gesham Magombedze, et al.. (2021). Novel Short-Course Therapy and Morphism Mapping for Clinical Pulmonary Mycobacterium kansasii. Antimicrobial Agents and Chemotherapy. 65(5). 7 indexed citations
15.
Chirehwa, Maxwell, Richard Court, Lubbe Wiesner, et al.. (2020). Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone. Antimicrobial Agents and Chemotherapy. 64(11). 19 indexed citations
16.
Davids, Malika, Anil Pooran, Clemens Hermann, et al.. (2019). A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live Bacillus Calmette-Guérin. American Journal of Respiratory and Critical Care Medicine. 201(10). 1277–1291. 30 indexed citations
17.
Court, Richard, Lubbe Wiesner, Maxwell Chirehwa, et al.. (2018). Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease. 22(8). 926–930. 1 indexed citations
18.
Srivastava, Shashikant, Carleton M. Sherman, Claudia Meek, Richard D. Leff, & Tawanda Gumbo. (2011). Pharmacokinetic Mismatch Does Not Lead to Emergence of Isoniazid- or Rifampin-Resistant Mycobacterium tuberculosis but to Better Antimicrobial Effect: a New Paradigm for Antituberculosis Drug Scheduling. Antimicrobial Agents and Chemotherapy. 55(11). 5085–5089. 37 indexed citations
19.
Gumbo, Tawanda, Arnold Louie, Mark R. Deziel, et al.. (2007). Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin. Antimicrobial Agents and Chemotherapy. 51(11). 3781–3788. 276 indexed citations
20.
Louie, Arnold, Mark R. Deziel, Weiguo Liu, et al.. (2005). Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity. Antimicrobial Agents and Chemotherapy. 49(12). 5058–5068. 142 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charles A. Peloquin Breakdown of academic impact, for papers by Eric L. Nuermberger Breakdown of academic impact, for papers by William Hope Breakdown of academic impact, for papers by Stephen H. Gillespie Breakdown of academic impact, for papers by Rob E. Aarnoutse Breakdown of academic impact, for papers by J Grosset Breakdown of academic impact, for papers by M. Hong Nguyen Breakdown of academic impact, for papers by Ethan Rubinstein Breakdown of academic impact, for papers by Véronique Dartois Breakdown of academic impact, for papers by Martin J. Boeree
Rankless by CCL
2026